Cero Therapeutics Holdings, Inc.
Clinical trials sponsored by Cero Therapeutics Holdings, Inc., explained in plain language.
Cero Therapeutics Holdings, Inc.
CERO
OTC
Biotech developing cellular therapies for cancer and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered T-Cells take on tough blood cancers in first human trial Results expected Dec 2026 (estimated)